• Explore /
  • Poster
  • / A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.

A phase 1b study of the anti-PD-1 monoclonal antibody BGB-A317 (A317) in combination with the PARP inhibitor BGB-290 (290) in advanced solid tumors.

Abstract Poster

Authors

null

Michael Friedlander

Prince of Wales Hospital, Randwick, Australia

Michael Friedlander, Tarek Meniawy, Ben Markman, Linda R. Mileshkin, Paul Harnett, Michael Millward, Joanne Lundy, Alison E. Freimund, Christie Norris, John Wu, Virginia Paton, Lai Wang, Bo Gao

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO-SITC Clinical Immuno-Oncology Symposium

Session Type

Poster Session

Session Title

Poster Session A

Track

Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Breast and Gynecologic Cancers,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Oncolytic Viruses,Hematologic Malignancies

Sub Track

Immune Checkpoints and Stimulatory Receptors

Clinical Trial Registration Number

NCT02660034

Citation

J Clin Oncol 36, 2018 (suppl 5S; abstr 48)

DOI

10.1200/JCO.2018.36.5_suppl.48

Abstract #

48

Poster Bd #

A3

Abstract Disclosures

Similar Posters

First Author: Michael Friedlander

First Author: Jayesh Desai

First Author: Jayesh Desai

First Author: Ecaterina Elena Dumbrava